A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation

Trial Profile

A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs GLPG 2737 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms PELICAN
  • Sponsors Galapagos NV
  • Most Recent Events

    • 28 Jun 2018 Primary endpoint has been met. (Change from baseline in sweat chloride concentration compared to placebo), according to a Galapagos NV media release.,
    • 28 Jun 2018 According to a Galapagos NV media release, details of this study will be presented at a future conference.
    • 28 Jun 2018 Results presented in a Galapagos NV media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top